GSK-1292263 is an orally available GPR119 agonist with pEC50s of 6.9 and 6.7 for human and rat GPR119, respectively. GSK-1292263 can be used for the research of type 2 diabetes mellitus (T2DM).
体内研究
GSK1292263 upregulates glucagon-like peptide-1 and enhances glucose-dependent insulin secretion and improves glucose homeostasis in type 2 diabetic rats.
Animal Model:
Male neonatal Streptozotocin (STZ)-induced SD rats (7 weeks of age)
Dosage:
30 mg/kg
Administration:
Orally given; once a day for 2 weeks
Result:
The AUC of plasma glucose (AUCPG) in the single treatment of the GSK1292263 group was numerically lower than that of the vehicle group, but the effect was modest.
分子式
C23H28N4O4S
分子量
456.56
CAS号
1032823-75-8
运输条件
Room temperature in continental US; may vary elsewhere.